Standard of Care Treatment and Rehabilitation
At a Glance
Short bowel syndrome treatment is individualized intestinal rehabilitation: intravenous nutrition and fluids may be needed while the bowel adapts, alongside anatomy-based eating and drinking plans, medicines, and selected therapies to reduce IV support.
The goal of Short Bowel Syndrome (SBS) treatment is intestinal rehabilitation: a coordinated effort to maximize your body’s ability to absorb what it needs while safely reducing your dependence on intravenous support [1][2]. This process is highly individualized and changes as your bowel adapts.
Note: The dietary and fluid options below must be clinician-supervised. HPN and oral fluid prescriptions must not be changed independently.
The Foundation: Intravenous Support
For many people with SBS, Parenteral Nutrition (PN) and intravenous (IV) fluids are the most critical treatments. PN provides a liquid mix of proteins, fats, carbohydrates, vitamins, electrolytes, trace elements, and minerals directly into your bloodstream [3].
- A Lifeline, Not a Failure: PN is the essential bridge that keeps you nourished while your bowel goes through the adaptation process [4].
- Home PN (HPN): Most patients transition to infusing their nutrition at home, often overnight, allowing for more freedom during the day [3].
- Monitoring: Your team will regularly check your weight, urine output, and bloodwork to adjust the “recipe” of your PN and ensure your liver and kidneys are staying healthy [5][6].
Customizing Your Diet by Anatomy
General healthy eating rules often do not apply to SBS. Your diet must be tailored to your specific anatomical subtype by your intestinal-failure team.
If you do NOT have a colon (Type 1: End-Jejunostomy):
- Separate Solids and Liquids: Drinking while eating can “wash” food through your system too quickly. Many experts recommend waiting 30 to 60 minutes between eating and drinking, if appropriate for your regimen [7].
- Limit Simple Sugars: High-sugar foods (like soda or juice) pull water into your gut, which can cause “dumping” and massive fluid loss [7].
- High Sodium: Because you lose a lot of salt through your stoma, you may need to add significant amounts of extra salt to your food, guided by your team [7].
If you DO have a colon (Type 2 or 3):
- Complex Carbohydrates: Your colon can ferment starches (like rice, pasta, and bread) into energy, which helps your body “salvage” calories [8].
- Watch for Oxalates: Having a colon in SBS increases the risk of oxalate kidney stones. You may need to limit high-oxalate foods like spinach, beets, and nuts, and take calcium supplements to bind these oxalates in the gut [9][10].
Oral Rehydration Solutions (ORS)
In patients with a high-output jejunostomy, drinking large amounts of hypotonic fluids (like plain water, tea, or coffee) can worsen net sodium and water losses. Instead, patients are taught to use a prescribed Oral Rehydration Solution (ORS) [11]. These specialized drinks contain a precise balance of salt and sugar that helps your gut pull water into your bloodstream [11]. You should not improvise an ORS recipe or substitute sports drinks without consulting your team.
Medication to Manage Symptoms
Several types of medications can help slow down your gut and reduce fluid loss. Dosing, timing, and stopping or starting these drugs must be prescribed by the treating team, as SBS regimens may use doses or schedules that differ from ordinary over-the-counter use:
- Antimotility Agents: Drugs like loperamide or codeine slow the movement of the gut [12][7]. Codeine can cause sedation, constipation, and dependence; excessive loperamide can cause serious cardiac toxicity.
- Antisecretory Meds: Proton pump inhibitors (PPIs) or H2 blockers reduce the amount of acid your stomach produces [12][13]. Prolonged acid suppression has risks including infection, hypomagnesemia, and possible worsening of bacterial overgrowth.
- Bile Acid Binders: If you have a colon and limited terminal-ileal resection, bile-acid diarrhea may benefit from binders like cholestyramine. However, extensive ileal resection can deplete the bile-acid pool; cholestyramine may then worsen fat-soluble-vitamin loss and interfere with other medicines. This requires specialist assessment [7][14].
Enterotrophic (Growth) Therapies
For selected adults who remain dependent on PN after their bowel has stabilized, specialized medications called GLP-2 analogues may be prescribed and monitored by the intestinal-failure team.
- Teduglutide: This is a daily injection that helps the intestinal “fingers” (villi) grow taller. A systematic review found that about 64% of patients had at least a 20% reduction in parenteral-support needs at 6 months, though complete independence is much less common [15]. Treatment requires endoscopic polyp surveillance, and monitoring for possible obstruction, biliary or pancreatic complications, and fluid overload [16][17][18].
- Glepaglutide: This is a newer GLP-2 analogue. Phase 3 clinical trials showed it can reduce the weekly volume of IV support needed, but it is approval-dependent by country and may be considered investigational [19].
Common questions in this guide
Why might I need parenteral nutrition for short bowel syndrome?
What should I drink if I have a high-output jejunostomy?
How does my anatomy affect my short bowel syndrome diet?
Can medicines reduce stool or stoma output in short bowel syndrome?
Could teduglutide help me need less intravenous support?
What are early signs that I may be dehydrated?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Secondary short bowel syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my specific target for daily urine volume, and what is the best way for me to track my 'ins and outs' at home?
- 2.Based on my anatomy, what should my specific ratio of carbohydrates to fats be, and should I be adding extra salt to my food?
- 3.Is my current stool/stoma output high enough to warrant adding an antisecretory medication like a proton pump inhibitor?
- 4.Am I a candidate for teduglutide, and if so, what are the specific steps for the required endoscopic screening?
- 5.Can you provide a recipe for an oral rehydration solution (ORS) that has the correct sodium-to-glucose ratio for my gut?
References
References (19)
- 1
Anatomical and physiological considerations in short bowel syndrome: Emphasis on intestinal adaptation and the role of enterohormones.
Tappenden KA
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2023; (38 Suppl 1()):S27-S34 doi:10.1002/ncp.10991.
PMID: 37115026 - 2
Treatment of short bowel syndrome: Breaking the therapeutic ceiling?
Wauters L, Joly F
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2023; (38 Suppl 1()):S76-S87 doi:10.1002/ncp.10974.
PMID: 37115030 - 3
ESPEN guidelines on chronic intestinal failure in adults.
Pironi L, Arends J, Bozzetti F, et al.
Clinical nutrition (Edinburgh, Scotland) 2016; (35(2)):247-307 doi:10.1016/j.clnu.2016.01.020.
PMID: 26944585 - 4
Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey.
Joly F, Jezerski D, Pape UF, et al.
Clinical nutrition (Edinburgh, Scotland) 2025; (47()):54-67 doi:10.1016/j.clnu.2025.01.026.
PMID: 39986179 - 5
Parenteral Nutrition and Intestinal Failure.
Bielawska B, Allard JP
Nutrients 2017; (9(5)) doi:10.3390/nu9050466.
PMID: 28481229 - 6
Nutritional Management of a Patient with a High-Output Stoma after Extensive Small Bowel Resection to Treat Crohn's Disease.
Lee YJ, Kweon M, Park M
Clinical nutrition research 2019; (8(3)):247-253 doi:10.7762/cnr.2019.8.3.247.
PMID: 31384603 - 7
Real-World Management of High Stool Output in Patients with Short Bowel Syndrome: An International Multicenter Survey.
Lakananurak N, Wall E, Catron H, et al.
Nutrients 2023; (15(12)) doi:10.3390/nu15122763.
PMID: 37375667 - 8
Starch Tolerance and the Short Bowel.
de Laffolie J, Naim HY, Rudloff S, Zimmer KP
Journal of pediatric gastroenterology and nutrition 2018; (66 Suppl 3()):S68-S71 doi:10.1097/MPG.0000000000001962.
PMID: 29762383 - 9
Dietary Management of Chronic Kidney Disease and Secondary Hyperoxaluria in Patients with Short Bowel Syndrome and Type 3 Intestinal Failure.
Adler M, Millar EC, Deans KA, et al.
Nutrients 2022; (14(8)) doi:10.3390/nu14081646.
PMID: 35458207 - 10
Risk Factors for Nephrolithiasis in Adults with Short Bowel Syndrome.
Yang J, Sun H, Wan S, et al.
Annals of nutrition & metabolism 2019; (75(1)):47-54 doi:10.1159/000502329.
PMID: 31434099 - 11
How to manage a high-output stoma.
Nightingale JMD
Frontline gastroenterology 2022; (13(2)):140-151 doi:10.1136/flgastro-2018-101108.
PMID: 35300464 - 12
Systematic review: pharmacotherapy for high-output enterostomies or enteral fistulas.
de Vries FEE, Reeskamp LF, van Ruler O, et al.
Alimentary pharmacology & therapeutics 2017; (46(3)):266-273 doi:10.1111/apt.14136.
PMID: 28613003 - 13
The safety of available treatment options for short bowel syndrome and unmet needs.
Pironi L, Raschi E, Sasdelli AS
Expert opinion on drug safety 2021; (20(12)):1501-1513 doi:10.1080/14740338.2021.1940947.
PMID: 34105428 - 14
Managing the Adult Patient With Short Bowel Syndrome.
Parrish CR, DiBaise JK
Gastroenterology & hepatology 2017; (13(10)):600-608.
PMID: 29230136 - 15
Positive clinical outcomes associated with use of glucagon-like peptide-2 (GLP-2) analogues in patients with intestinal failure: A systematic review and meta-analysis.
Bastas A, Williams K, Wong D
Clinical nutrition ESPEN 2025; (71()):102817 doi:10.1016/j.clnesp.2025.11.132.
PMID: 41344401 - 16
De Novo Development of Distal Jejunal and Duodenal Adenomas After 41 Months of Teduglutide Treatment in a Patient With Short-Bowel Syndrome: A Case Report.
Pevny S, Pape UF, Elezkurtaj S, et al.
JPEN. Journal of parenteral and enteral nutrition 2021; (45(3)):652-656 doi:10.1002/jpen.1982.
PMID: 32740933 - 17
Gastric Foveolar Hyperplastic Polyps in 2 Children With Short Bowel Syndrome on Long-Term Teduglutide.
Salazar JA, Goldsmith JD, Jimenez L, et al.
JPGN reports 2023; (4(4)):e389 doi:10.1097/PG9.0000000000000389.
PMID: 38034466 - 18
Use of teduglutide in adults with short bowel syndrome-associated intestinal failure.
Pironi L, Allard JP, Joly F, et al.
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2024; (39(1)):141-153 doi:10.1002/ncp.11015.
PMID: 37294295 - 19
Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial.
Jeppesen PB, Vanuytsel T, Subramanian S, et al.
Gastroenterology 2025; (168(4)):701-713.e6 doi:10.1053/j.gastro.2024.11.023.
PMID: 39708985
This page explains short bowel syndrome treatment and intestinal rehabilitation for informational purposes only and does not constitute medical advice. Do not change parenteral nutrition, fluids, diet, or medicines without guidance from your intestinal-failure team.